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Abstract 
Background: Human immunodeficiency virus (HIV) infection leads to decreased reverse cholesterol transport 
(RCT) in macrophages, and Nef mediated down-regulation and redistribution of ATP-binding cassette transporter A1 
(ABCA1) are identified as key factors for this effect. This may partially explain the increased risk of atherosclerosis in HIV 
infected individuals. Since endothelial dysfunction is key in the initial stages of atherosclerosis, we sought to deter-
mine whether RCT was affected in human aortic endothelial cells (HAECs).
Results: We found that apoA-I does not significantly stimulate cholesterol efflux in HAECs while cholesterol efflux to 
high-density lipoprotein (HDL) was dramatically reduced in HAECs co-cultured with HIV infected cells. Studies with 
wild type and Nef defective HIV revealed no significant differences suggesting that multiple factors are working per-
haps in concert with Nef to affect cholesterol efflux to HDL from HAECs. Interestingly, treating HAECs with recombi-
nant Nef showed similar effect in HDL mediated cholesterol efflux as observed in HAECs co-cultured with HIV infected 
cells. Using a detergent-free based subcellular fractionation approach, we demonstrated that exposure of HAECs to 
HIV infected cells or Nef alone disrupts caveolin 1 (Cav-1) subcellular trafficking upon HDL stimulation. Moreover, Nef 
significantly enhanced tyrosine 14 phosphorylation of Cav-1 which may have an impact on recycling of Cav-1 and 
caveolae.
Conclusion: These results suggest that HIV interferes with cholesterol efflux by HDL in HAECs through the disruption 
of Cav-1s’ cellular distribution and that multiple factors are involved, possibly including Nef, for the inhibition of HDL 
mediated cholesterol efflux and alteration of cellular distribution of Cav-1.
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Background
Human immunodeficiency virus (HIV) infection is asso-
ciated with high cardiac risks. An accumulating body of 
evidence suggests that HIV infection leads to accelerated 
atherosclerosis [1, 2]. Macrophages, smooth muscle cells 
(SMCs) and vascular endothelial cells are prominent cell 
types involved in the progression of atherosclerosis. Key 
features for atherosclerosis include the accumulation of 
cholesterol in macrophages and SMCs leading to foam 
cell formation, and vascular endothelial cell dysfunction, 
which is considered an early marker for atherosclerosis 
[3–5]. HIV has been shown to infect human arterial 
SMCs, and HIV p24 protein has been detected in SMCs 
from tissue sections of human atherosclerotic plaques 
obtained from HIV-infected individuals [6]. HIV infec-
tion can change endothelial cell function as well as the 
microenvironment that influences endothelium function 
[7–9]. Studies in both animal and in vitro models reveal 
a correlation of endothelial cell dysfunction with HIV 
envelope gp120, Nef, Tat, and matrix p17 [10–14]. These 
changes include enhanced expression of cell adhesion 
molecules, increased permeability of endothelial cells, 
stimulation of cytokine secretion, endothelial cell prolif-
eration, and apoptosis [10–14]. Furthermore, HIV infec-
tion leads to impaired ATP-binding cassette transporter 
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A1 (ABCA1)-dependent cholesterol efflux from human 
macrophages, which is mediated by Nef induced post-
transcriptional down-regulation as well as redistribution 
of ABCA1 [15]. HIV positive foam cells are present in 
atherosclerotic plaques of HIV infected patients [15]. Nef 
treated mice have significantly increased amounts of lipid 
laden macrophages [16]. These results suggest that direct 
infection of human macrophages and arterial SMCs by 
HIV, as well as HIV induced endothelial cell dysfunction 
are involved in a potential mechanism in a multifactorial 
paradigm to explain atherosclerosis progression during 
HIV infection.
Reverse cholesterol transport (RCT) and cholesterol 
efflux is a pathway to transport accumulated cholesterol 
from vessel walls to the liver for excretion. By reducing 
cholesterol from vessel walls, RCT may affect atheroscle-
rosis progression. High-density lipoprotein (HDL) is the 
main acceptor for cholesterol efflux from cells and con-
sidered a protector against atherosclerosis because of 
its role in RCT [17, 18]. There is substantial information 
on the influence of HIV infection on macrophage RCT, 
while the impact on endothelial cell RCT as well as the 
potential effects on endothelial cell function during HIV 
infection is not clearly known.
Caveolin-1 (Cav-1), an integral membrane protein of 
21- to 24-kDa size, is a major structural component of 
caveolae and it binds to cholesterol [19]. This molecule 
was first identified as a major tyrosine-phosphorylated 
substrate of v-src [20] and is involved in multiple cellu-
lar functions including signal transduction, cholesterol 
trafficking and efflux, and endocytosis and transcyto-
sis processes [21, 22]. Cav-1 is particularly abundant in 
endothelial cells and is crucial for the function of these 
cells. In endothelial cells, Cav-1 and caveolae may play a 
proatherogenic role. Cav-1 and caveolae promote trans-
cytosis of low-density lipoprotein (LDL)-cholesterol par-
ticles from the blood to sub-endothelial spaces [23]. HDL 
co-localizes with Cav-1 on the cell surface of cholesterol-
loaded endothelial cells, and as a consequence, caveolae 
act as major platforms to facilitate the transport of excess 
cholesterol to HDL on aortic endothelial cell surfaces 
[24].
The relationship between HIV and host factors deter-
mines the modulation of various cellular functions and 
replication of virus within an infected individual. There 
is limited information on the relationship of HIV infec-
tion and Cav-1. Recently, binding of Cav-1 to HIV enve-
lope in the lipid rafts has shown to inhibit cell fusion 
and subsequently blocks envelope mediated bystander 
killing [25, 26]. Cav-1 expression is induced significantly 
in macrophages through a Tat mediated signaling path-
way leading to the suppression of HIV replication [27]. 
In macrophages, Cav-1 overexpression restores Nef 
mediated impairment of cholesterol efflux to apoA-I [28]. 
Cav-1 within endothelial cells can act as a proathero-
genic protein [29, 30], however, the potential role of 
Cav-1 in regulating lipid metabolism in endothelial cells 
and the relative importance of Cav-1 in the regulation of 
endothelial function under HIV infection is not known. 
To gain insight into the influence of HIV on lipid metab-
olism in endothelial cells we evaluated HDL mediated 
cholesterol efflux and correlated with the dynamic dis-
tribution of Cav-1. In addition, we show that recombi-
nant Nef affects the redistribution of Cav-1 in cholesterol 
loaded endothelial cells upon HDL stimulation perhaps 
by inducing phosphorylation of Cav-1.
Results
HIV impairs cholesterol efflux by HDL in endothelial cells
The endothelium plays an essential role in cardiovascu-
lar health; therefore, endothelial dysfunction is a criti-
cal early element in the pathogenesis of atherosclerosis 
which contributes to plaque initiation and progression 
[4, 18]. Human aortic endothelial cells (HAECs) also 
have direct contact with circulating HIV infected cells 
as well as released viral proteins [31], and we therefore 
investigated the influence of HIV infection on endothelial 
cholesterol homeostasis by monitoring cholesterol efflux 
in HAECs. We first examined lipid free apoA-I medi-
ated cholesterol efflux in HAECs co-cultured with HIV 
infected cells. Our results showed that unlike human 
macrophages apoA-I did not significantly stimulate cho-
lesterol efflux in HAECs (Additional file  1: Figure S1). 
This may be due to weak expression of ABCA-1 in the 
HAECs [32, 33]. The inefficient apoA-I mediated choles-
terol efflux in HAECs was monitored with cells activated 
with liver X receptor (LXR) agonist TO-901317 to stimu-
late ABCA1 expression and cholesterol efflux. Our results 
showed that after TO-901317 treatment apo-AI did not 
significantly promote cholesterol efflux (P ˃ 0.05) (Addi-
tional file 1: Figure S1). These results correlate with low 
expression levels of ABCA1 in HAECs and TO-901317 
treatment (3  µM) barely elevated endogenous ABCA1 
expression in HAECs (Additional file  1: Figure S1) thus 
confirming that apoA-I does not significantly promote 
cholesterol efflux in HAECs, which is consistent with 
Liao et al. previous observations [34].
We then monitored whether HDL mediated choles-
terol efflux would be affected in HAECs co-cultured with 
HIV infected cells. HDL stimulated cholesterol efflux 
from HAECs after co-culture with ACH2 was markedly 
decreased with the reduction reaching 46% as compared 
to HAECs cultured alone (Figure 1a). The reduction was 
also evident when HAECs were co-cultured with HUT-
78HIV and U1HIV showing a decrease by 32 and 30%, 
respectively. We observed no reduction in HDL mediated 
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cholesterol efflux when the endothelial cells were co-cul-
tured with uninfected parental A3.01, HUT-78 or U937 
cells (Figure  1b). In addition, we compared HDL medi-
ated cholesterol efflux in HAECs co-cultured with HIV 
infected cells (HUT-78HIV) in varying ratios and dif-
ferent co-culture time points. As shown in Figure 1c the 
1:1 ratio showed no significant decrease whereas the 1:5 
ratio showed a 56% decrease in HDL mediated choles-
terol efflux. A ratio of HAECs:HUT-78HIV of 1:3 showed 
a decrease in HDL mediated cholesterol efflux of 44% at 
day 7, whereas no significant reduction was observed at 
day 3 (Figure 1d). Furthermore, HAECs were co-cultured 
with phorbol 12-myristate 13-acetate (PMA) stimulated 
and unstimulated U1HIV cells to further demonstrate 
that HIV affects HDL mediated cholesterol efflux of 
endothelial cells. When endothelial cells were cultured 
with PMA stimulated U1HIV cells HDL mediated cho-
lesterol efflux was reduced by 44% (Figure 1e). There was 
only a slight decrease when the endothelial cells were 
cultured with unstimulated U1HIV cells. PMA treated 
control uninfected U937 had no influence on HDL medi-
ated cholesterol efflux. Taken together these results show 
that HIV has an impact on HDL mediated cholesterol 
efflux in endothelial cells.
Expression levels of Cav‑1, ABCA1, ABCG1, and SR‑B1 
in endothelial cells
Cholesterol trafficking and efflux are regulated by vari-
ous molecules that include two ATP-binding membrane 
cassette transport proteins (ABCA1 and ABCG1) cells, 
scavenger receptor type B class I (SR-BI), and Cav-1 [24, 
33]. To reveal the mechanism underlying HIV mediated 
impairment of cholesterol efflux in endothelial cells we 
examined the expressions of Cav-1, ABCA1, SR-B1 and 
ABCG1 in HAECs co-cultured with HIV-infected cells 
or cultured alone by Western blot analysis. As shown in 
Figure  1f, the baseline expression of ABCA1 in HAECs 
is low and there is a slight decrease in ABCA1 when the 
a b c
d e f
Figure 1 HIV impairs HDL mediated cholesterol efflux from HAECs. a HAECs co-cultured with HIV infected ACH2, U1HIV and HUT-78HIV, or b unin-
fected parental cell lines A3.01, U937 or HUT-78. HDL induced cholesterol efflux from HAEC was examined. c HAECs and HUT-78HIV were co-cul-
tured with different HAEC/HUT-78HIV ratios 1:1 or 1:5 for 7 days, and cholesterol efflux measured. d HAECs were co-cultured with HUT-78HIV at ratio 
1:3 and HDL mediated cholesterol efflux at days 3 and 7 were analyzed. e U1HIV and control cells U937 were pretreated with PMA (10−8 M) for 48 h 
before co-culture, and HAECs were co-cultured with those cells for 7 days and further subjected to cholesterol efflux examination. f The expression 
levels of ABCA1, ABCG1, SR-B1, and Cav-1 in HAECs. HAECs were co-cultured with HIV infected cells ACH2, HUT78HIV and U1HIV for 5 days. The 
expressions of ABCA1, ABCG1, SR-BI and Cav-1 HAECs were examined by Western blotting. Representative Western blots are shown. Mock HAECs 
cultured alone, w/sti PMA treated; *P < 0.05 compared with control cells.
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endothelial cells were co-cultured with HIV-infected 
cells. In contrast, the abundant expression of Cav-1 is evi-
dent. However, the expression levels of Cav-1 remained 
similar whether endothelial cells were co-cultured with 
HIV infected cells or not. Moreover, the expression lev-
els of ABCG1 and SR-BI remained the same whether the 
endothelial cells were co-cultured with infected cells or 
not. Therefore, the expression levels ABCA1, ABCG1, 
SR-BI and Cav-1 in HAECs co-cultured with HIV 
infected cells are not significantly affected.
Cav‑1 distribution in endothelial cells co‑cultured with HIV 
infected cells
Caveolae are the main structural platforms facilitating 
the transport of excess cholesterol to HDL on the aortic 
endothelial cell surface. Cav-1 functions as an intracel-
lular cholesterol transporter, and cholesterol trafficking 
by Cav-1 is critical for HDL stimulated cholesterol efflux 
[24]. In addition, subcellular distribution of Cav-1 is an 
important parameter that influences endothelial cell 
functions including cholesterol homeostasis [35–37]. 
Therefore, Cav-1s’ subcellular localization and recy-
cling have an effect on cholesterol efflux. To determine 
whether HIV can impact the cellular distribution of 
Cav-1 in endothelial cells, consequently impacting cho-
lesterol efflux to HDL, HAECs were co-cultured with 
HIV-infected cells and subjected to sucrose gradient 
fractionation. The sodium carbonate-based fractiona-
tion method was used to isolate the low-density caveo-
lae-enriched membranes. After sucrose density gradient 
ultra-centrifugation 12 fractions were obtained, and 
aliquots from each fraction were examined by Western 
blotting. As shown in Figure 2a Flotilin-1, a marker for 
caveolae enriched membranes, was observed in fraction 
5, which usually presents in fractions 4 and 5. β-tubulin 
on the other hand, a marker for cytoplasmic compo-
nents, was strictly restricted to fractions 8–12 showing 
no contamination among the caveolar fractions. The 
density of each fraction was monitored and a linear den-
sity gradient is shown in Figure  2b. In order to mimic 
hypercholesterolemia in HAECs cholesterol at 40  µg/
ml was loaded onto the HAECs by incubating them in 
serum free medium containing 1% fatty acid free BSA, 
which significantly increased cellular cholesterol content 
(Additional file  2: Figure S2) compared to endothelial 
cells cultured in basal medium. Cav-1 was highly present 
in lower-density fractions 4 and 5 (caveolae fractions) 
with significantly lower amounts in the higher-density 
fractions 9–12 when endothelial cells were cultured 
alone in a regular endothelial cell culture basal medium 
(Figure 3a). In the presence of cholesterol Cav-1 distri-
bution shifted, with increased amounts, towards the 
lower density caveolar fractions 4–5 (Figure 3b). When 
HDL was provided in cholesterol treated endothelial 
cells (Figure  3c), Cav-1 increased significantly in the 
non-caveolar fractions 9–10 with reductions in fractions 
4–5 indicating an increase in recycling of Cav-1 from 
the membrane to the cytoplasm when HDL mediated 
cholesterol efflux is taking place. Interestingly, when 
the endothelial cells were co-cultured with HUT-78HIV 
cells (HIV infected) the distribution of Cav-1 shifted 
towards the lower density fractions 4–5 similar to that of 
endothelial cells cultured alone in the presence of cho-
lesterol (Figure 3d). The distribution of Cav-1 remained 
in fractions 4–5, the caveolar fractions, in the endothelial 
cells co-cultured with HIV infected cells whether choles-
terol or cholesterol/HDL was provided or not (Figure 3e, 
f ). Furthermore, compared to the control (Figure  3c) 
there is a significantly lower shift of Cav-1 from fractions 
4–5 into non-caveolar fractions 6–11 upon HDL stimu-
lation (Figure  3f ). These findings show that HIV alters 
the normal Cav-1 subcellular localization/redistribution 




Figure 2 Sodium carbonate extraction and sucrose gradient isola-
tion of caveolae membrane fractions. HAECs were homogenized 
and separated by a detergent-free (Na2CO3) based discontinuous 
sucrose density centrifugation. a Twelve fractions were collected 
from the gradient going from low to high density and were analyzed 
by Western blotting with antibody for specific markers of caveolae 
(Cav-1, Flotilin-1) β-tubulin (cytoplasmic components). b Density of 
each fraction was measured.
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The potential impact of Nef on cholesterol efflux by HDL 
in endothelial cells
The Nef protein has been shown to be the key molecule 
for the impairment of ABCA1 dependent cholesterol 
efflux by apoA-I of HIV infected macrophages [15]. Since 
our results showed that apoA-I mediated cholesterol 
efflux was not significantly affected in HAECs we exam-
ined the influence of Nef on HDL mediated cholesterol 
efflux in these cells. HAECs were co-cultured with cells 
infected with NL4-3 wild type (HIVWT) or Nef defec-
tive (HIVNef−) HIV strain and co-cultured with HAECs. 
HDL stimulated cholesterol efflux from HAECs after 
co-culture with HIV infected cells was significantly 
decreased with the reduction reaching 67 and 54% in 
HAECs co-cultured with both wild type and Nef defec-







Figure 3 Cav-1 redistribution in HAECs co-cultured with HIV-infected cells during HDL mediated reverse cholesterol transport. HAECs were 
cultured in regular ECM (basal medium) (a), or serum free medium containing 1% fatty acid free BSA and cholesterol (40 µg/ml) for 36 h, and 
then further incubated in serum free medium without HDL (b) or with HDL (c) for 1–2 h. HAECs were then subjected to sucrose density gradient 
fractionation. Cav-1 distribution from discontinuous sucrose density gradient was examined by immunoblots. d HAECs were co-cultured with HUT-
78HIV cells for 5 days, and HAECs were placed in regular ECM medium (cocul/HUT78HIV basal). After 5 days co-culturing with HUT-78HIV, HAECs 
were placed in serum free medium in the presence of cholesterol (40 µg/ml) and 1% fatty acid free BSA, and then followed incubation in medium 
e without HDL or f with HDL for 1–2 h. Using Na2CO3 based sucrose density gradient fractionation, 12 fractions were obtained and examined by 
Western blotting for Cav-1 distribution. Representative data are shown from three independent experiments. The ratio of Cav-1 distribution from 
mock or HUT-78HIV co-cultured HAECs in Cav-1 enriched membrane fractions 4–5 and non-caveolar fractions 6–8 and 9–12 based on three inde-
pendent experiments are shown at the bottom. Dash lines refer to caveolae enriched membrane fractions 4 and 5.
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alone or 78 and 69% compared with uninfected cells (Fig-
ure  4a). Comparative analysis of HDL mediated choles-
terol efflux for HAECs co-cultured with wild type and Nef 
defective HIV revealed that there was a minor decrease 
that is not significant in HDL mediated cholesterol efflux 
with the wild type compared to that of the Nef defec-
tive HIV. In addition, HDL mediated cholesterol efflux 
was measured in HAECs treated with supernatant from 
wild type or Nef defective HIV infected cells. As shown 
in Figure 4b cholesterol efflux from HAECs treated with 
supernatants from wild type HIV infected cells shows 
that there was no significant difference compared to that 
of Nef defective. These results taken together suggest that 
during co-culture multiple factors are working to affect 
cholesterol efflux to HDL in HAECs. If Nef plays a role 
then there are other factors that must have saturated 
HDL cholesterol efflux to not see the difference between 
the wild type and Nef defective HIV.
To further explore the influence of Nef in HDL medi-
ated cholesterol efflux in HAECs we determined the 
level of Nef released from the infected cells we used to 
investigate HDL cholesterol efflux and caveolin 1 re-dis-
tribution by Western blot analysis. As shown in Figure 5a 
there is a significant amount Nef expression in cell lysate. 
TCA precipitation was needed to see Nef released into 
the media. These results imply that the low of level Nef 
released from infected cells and a possible saturation of 
HDL mediated cholesterol efflux by other cellular factors 
and viral proteins may have overshadowed any potential 
role in cholesterol efflux by Nef. We, therefore, measured 
the level of HDL mediated cholesterol efflux from HAECs 
cultured with varying concentrations of recombinant 
Nef. As shown in Figure 5b a Nef dose dependent reduc-
tion of cholesterol efflux was observed with a decrease 
of 9, 19, or 30% when the HAECs were cultured with 
concentrations of 20, 50, or 100 ng/ml Nef, respectively. 
Therefore, Nef participates in suppressing HDL medi-
ated cholesterol efflux in endothelial cells. The expression 
levels of Cav-1, ABCA1, ABCG1 and SR-BI were exam-
ined in the presence of Nef to determine whether HDL 
mediated cholesterol efflux suppression by Nef could be 
due to changes in expression of these molecules that are 
important in cholesterol metabolism. Similar to what 
was observed with co-culture of HIV infected cells the 
expression of ABCA1 was low with a minor effect that 
is not significant in Nef treated cells (Figure  5c). Con-
sistent with HAECs co-cultured with HIV-infected cells 
the expression of Cav-1, ABCG1 and SR-BI remained 
the same whether the cells were treated with Nef or not. 
These results suggest that impaired cholesterol efflux to 
HDL from HAECs by HIV or recombinant Nef is not due 
to expression levels of ABCA1, ABCG1, SR-BI or Cav-1.
Nef treatment alters Cav‑1 distribution during HDL 
stimulation
Our results show that Nef influences HDL mediated cho-
lesterol efflux in endothelial cells, therefore, we exam-
ined whether Nef plays a role in the alteration of the 
cellular distribution of Cav-1 as we observed above by 
HIV. HAECs were cultured in the presence of Nef and 
the cells were then incubated with cholesterol contain-
ing medium in the absence or presence of HDL. Sucrose 
density gradient subcellular fractionations were sub-
jected to immunoblot analysis to determine the levels of 
Cav-1 in each fraction. Untreated cells with cholesterol 
and HDL showed a redistribution of Cav-1 from lower 
(4–5) to higher (9–11) density fractions (Fig.  6a–c). In 
the presence of Nef Cav-1 mainly remained enriched in 
the caveolae fractions 4–5 similar to endothelial cells co-
cultured with HIV infected cells (Figure  6d). Cav-1 was 
also enriched in fractions 4–5 with cholesterol loading 
in the presence or absence of HDL (Figure  6e, f ), sug-
gesting that Nef plays an important role in influencing 
a
b
Figure 4 HDL mediated cholesterol efflux in HAECs co-cultured 
with wild type or Nef defective HIV infected cells. a SupT1 cells were 
infected with pBR43IeG-nef+ (HIV WT) or pBR43IeG-nef− (HIV Nef−). 
Twenty-four hours post infection cells were co-cultured with HAECs 
for 5 days and cholesterol efflux to HDL in HAECs was measured. b 
HAECs were treated with supernatants from uninfected, wild type, 
or Nef defective infected SupT1 and cholesterol efflux to HDL was 
analyzed 5 days post supernatant treatments.
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Cav-1 redistribution and alteration of HDL mediated 
cholesterol efflux by HIV. The decrease is also more pro-
nounced in the presence of cholesterol and HDL similar 
to cells co-cultured with HIV infected cells. Therefore, 
Nef affects the subcellular distribution of Cav-1 conse-
quently contributing to the inhibition of HDL mediated 
cholesterol efflux in endothelial cells.
Nef stimulates Cav‑1 phosphorylation
Src phosphorylation of Cav-1 tyrosine 14 (Tyr14) 
is tightly associated with the regulation of multiple 
endothelial functions including endocytosis, transcy-
tosis and permeability [38–43]. In addition, cholesterol 
transport by caveolae also shares many features with the 
caveolae endocytic process and is modulated by Src acti-
vation [44, 45], thus Cav-1 Tyr14 phosphorylation can 
affect Cav-1 trafficking. Since Nef has been shown to 
influence the activity of Src kinases we speculated that 
the disruption of Cav-1 distribution by Nef might have to 
do with Nef inducing phosphorylation of Cav-1. There-
fore, we examined the Tyr14 phosphorylation of Cav-1 in 
endothelial cells treated with Nef at different time inter-
vals for 60  min. As shown in Figure  7a, b, Nef induced 
Cav-1 phosphorylation at Tyr14 at the 15 min time point 
reaching a maximum level at 30  min. Oxidative stress 
induces Tyr14 phosphorylation of Cav-1 by activating Src 
kinases and Nef is shown to induce oxidative stress. Thus 
reactive oxygen species (ROS) production was measured 
in endothelial cells co-cultured with HIV infected cells. 
As shown in Figure 7c ROS production was significantly 
enhanced in HAECs co-cultured with HUT-78HIV as 
compared to the control mock and endothelial cells co-
cultured with uninfected HUT-78 cells. In addition, Nef 
treatment significantly activates ROS production within 
an hour of addition (Figure  7d). These results suggest a 
potential role for Nef induced Tyr14 phosphorylation of 
Cav-1 in the HIV mediated disruption of Cav-1 subcellu-
lar distribution and alteration of cholesterol transport to 
HDL. Furthermore, the phosphorylation of Cav-1 by Nef 
could be mediated through Nef induced ROS activation.
Discussion
Human immunodeficiency virus regulates RCT in 
macrophages leading to the accumulation of choles-
terol in macrophages followed by foam cell transfor-




Figure 5 Influence of Nef on HDL mediated cholesterol efflux from HAECs. a Expression levels of Nef from HIV infected cells. Cell lysates and TCA 
and acetone precipitated culture media supernatants from infected cells were subjected to immunoblotting to detect Nef. Lanes 1 through 3 
represent released Nef from HIV infected cells and Lanes 4 through 6 from HIV infected cell lysates. b HAECs were treated with recombinant Nef at 
indicated concentrations for 72 h, and then HDL mediated cholesterol efflux was analyzed. *P < 0.05 compare with control cells, Mock non-treated 
HAECs. c HAECs were exposed to recombinant Nef (0–150 ng/ml) for 48 h. The expressions of ABCA1, ABCG1, SR-BI and Cav-1 as well as eNOS from 
above HAECs were examined by Western blotting. Representative Western blots are shown.
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atherosclerotic diseases. However, the alteration of RCT 
and cholesterol efflux within vascular endothelial cells 
remains unsolved. Cav-1 is expressed in macrophages, 
SMCs and vascular endothelial cells, the three prominent 
cell types which are all involved in atherosclerosis. This 
molecule, which is particularly enriched in endothelial 
cells and the most prominent component of endothelial 
caveolae, is considered a crucial regulator for choles-
terol homeostasis in vascular endothelial cells [21, 22, 29, 
30, 46]. Endothelial dysfunction is considered an early 
marker for atherosclerosis and well-established response 
to cardiovascular risk [4, 5, 18, 47, 48]. In this study, we 
investigated cholesterol efflux in HAECs co-cultured with 







Figure 6 Cav-1 localization in Nef treated HAECs. a Cav-1 distribution was examined in HAECs cultured in regular ECM basal medium using sucrose 
density gradient subcellular fractionation and immunoblots. b Cav-1 distribution in HAECs incubated in medium containing 40 µg/ml cholesterol 
and 1% fatty acid free BSA. c Cav-1 distribution in fractions was measured in cells pre-incubated with cholesterol for 36 h followed by incubation in 
serum free medium containing HDL for 2 h. d Cav-1 localization in sucrose density fractions was examined after HAECs were incubated in regular 
ECM medium (basal) in presence of HIV Nef for 3 days. e HAECs were treated with Nef for 3 days, then incubated in medium containing 40 µg/ml 
cholesterol and 1% fatty acid free BSA for 36 h, followed by a 2 h incubation in serum free medium without or f with HDL. Ratio of Cav-1 distribution 
from mock or Nef treated HAECs in Cav-1 enriched membrane fractions 4–5 and non-caveolar fractions 6–8 and 9–12 is shown at the bottom. Dash 
lines refer to caveolae enriched membrane fractions 4 and 5. Representative data are shown from three independent experiments.
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efflux to HDL is significantly reduced in endothelial cells 
when co-cultured with HIV-infected cells. There was no 
significant difference in HDL mediated cholesterol efflux 
in endothelial cells co-cultured with wild type or Nef 
defective HIV suggesting multiple factors are involved in 
HIV induced suppression of HDL mediated cholesterol 
efflux in HAECs. Furthermore, the reduction is related 
to impaired Cav-1 redistribution upon HDL stimulation. 
Interestingly, treatment of HAECs with recombinant Nef 
revealed a similar effect as HIV infection on cholesterol 
efflux and Cav-1 redistribution. In addition, Nef induced 
phosphorylation of Cav-1 at Tyr14 in the endothelial 
cells, which can influence Cav-1 redistribution. These 
results show that there is an HIV mediated disruption 
of cholesterol efflux in endothelial cells, and Cav-1 plays 
an important role in this process through a change in its 
trafficking with Nef possibly contributing to these altera-
tions by inducing phosphorylation of Cav-1 Tyr14.
High-density lipoprotein classically functions in the 
RCT removing cholesterol from peripheral tissues to the 
bloodstream. Our results show that HIV impairs HDL 
mediated cholesterol efflux in endothelial cells and that 
Nef possibly plays a role in this impairment. Interestingly, 
apoA-I mediated cholesterol efflux was not significant in 
endothelial cells whether HIV infected cells are present 
or not, possibly due to low-level endogenous ABCA1 
expression. The low level of ABCA1 expression is con-
sistent with studies from others and their results also 
showed that HDL but not lipid-free apoA-I promotes 
cellular cholesterol efflux in human umbilical vascular 
endothelial cells and HAECs under normal conditions 
[32, 33]. The failure to stimulate ABCA1 dependent cho-
lesterol efflux to apoA-I in endothelial cells in both the 
presence and absence of HIV shows that ABCA1 is not 
a major factor in the impairment of RCT from endothe-
lial cells, which is different from previous findings in HIV 
infected macrophages.
Cav-1 dependent signal transduction and cholesterol 
trafficking is essential to maintain cellular cholesterol 





Figure 7 Nef induced Cav-1 phosphorylation in HAECs. a HAECs were grown to 80–90% confluence. After changing to fresh growth medium, 
HAECs were exposed to Nef for 0–60 min. Phosphorylation of Cav-1 (Tyr14) was determined by Western blotting. The blots are representative of 
three separate experiments. b Relative density of phosphorylation protein (Phos Cav-1/total Cav-1) is shown. c Increased ROS production in HAECs 
co-cultured with HIV infected HUT-78 cells at ratio of 1:5 for 3 h. d Increased ROS production in HAECs treated with Nef at different time points.
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and co-localizes with HDL in cholesterol loaded endothe-
lial cells, indicating caveolae are the major cellular plat-
forms facilitating the transport of excess cholesterol to 
HDL on the cell surface of aortic endothelial cells [24, 
33]. The impact of HIV on the trafficking of Cav-1 as well 
as HDL mediated cholesterol efflux in endothelial cells 
would then affect RCT leading to impaired endothelial 
function. Our results demonstrate HIV or recombinant 
Nef affects the redistribution of Cav-1 in cholesterol 
loaded endothelial cells upon HDL stimulation. Nef has 
been shown to present on surface of infected cells [49], 
and is also known to be secreted from infected cells [50–
52] and exists in infected patients serum [52]. Nef can be 
secreted from monocytes and T cells that circulate in the 
blood stream. This protein is found in the blood stream 
at significant levels [52]. Furthermore, released Nef is 
shown to enter into uninfected cells inducing changes in 
the recipient cells [53–58]. Therefore, Nef can be released 
from infected cells and enter endothelial cells which then 
subsequently modulate Cav-1 cellular distribution alter-
ing HDL mediated cholesterol efflux. The reason we have 
not seen a significant difference in HAECs between wild 
type and Nef defective HIV could be due to a saturation 
effect on cholesterol efflux by other factors and a higher 
amount of Nef is needed to demonstrate the impact of 
Nef on HDL mediated cholesterol efflux. Alternatively, 
since Nef released from infected cells is associated with 
exosomes the influence on HDL mediated cholesterol 
efflux may not be as efficient as using recombinant Nef.
Post-transcriptional modification is important for 
Cav-1 function in cholesterol homeostasis. It is well doc-
umented that Src phosphorylation of Cav-1 is a require-
ment for activation of the caveolar transport machinery 
[38–42]. In fact, cholesterol-induced translocation of 
Cav-1 is modulated by Src activation [44]. In addition, 
elevated cholesterol stimulates caveolar endocytosis. This 
process also requires Src kinase and can be modulated 
by altering the balance of cholesterol and Cav-1 at the 
plasma membrane [45]. Src kinase induced phosphoryla-
tion of Cav-1 dependent signaling is crucial for endothe-
lial function. Cav-1 phosphorylation at Tyr14 is required 
for integrin-regulated caveolae internalization [59]. Our 
results, for the first time, shows that Nef induces Cav-1 
phosphorylation at Tyr14. This establishes a basis for a 
link of the association of Nef induced Cav-1 phosphoryl-
ation for increased endothelial dysfunction and athero-
sclerosis in HIV infection derived lipid disorders. Cav-1 
phosphorylation is important in caveolae formation and 
internalization [59, 60]. However, further study is needed 
to determine whether phosphorylation of Cav-1 at Tyr14 
by Nef affects endothelial caveolae dynamics, contribut-
ing to changes in Cav-1 distribution upon HDL stimu-
lated cholesterol efflux.
Conclusion
The present studies provide the first evidence for the 
regulation of endothelial cell RCT by HIV. The intracellu-
lar dynamic distribution of Cav-1 in vascular endothelial 
cells upon HDL stimulation was impacted in the pres-
ence of HIV infected cells or recombinant Nef. Induc-
tion of phosphorylation of Cav-1 by Nef observed may 
be a clue to further dissect the molecular mechanisms of 
these HIV induced changes in endothelial cells. Further-
more, our findings establish that HIV impairs HDL medi-
ated cholesterol efflux in endothelial cells. Recombinant 
Nef also has a similar effect on HDL mediated cholesterol 
efflux in endothelial cells. Taken together these data show 
the role of Cav-1 in the regulation of RCT in HAECs 
by HIV which can lead to endothelial cell dysfunction 
and provides a novel candidate to target for modulating 




Human aortic endothelial cells (HAECs), originally iso-
lated from human aorta, were purchased from ScienCell 
Research Laboratories. Recommended endothelial cell 
culture medium (ECM, ScienCell Research Laborato-
ries, Carlsbad, CA, USA) was used for the culturing of 
HAECs. HAECs at passages 4–7 were used in all experi-
ments. SupT1, ACH2, A3.01, HUT-78HIV, HUT-78, and 
U1HIV were kindly provided by the NIH AIDS Research 
Program. SupT1 cells were cultured in RPMI-1640 con-
taining 10% FBS and penicillin–streptomycin (100  µg/
ml). ACH2 is a cloned T-lymphocyte cell derived from 
A3.01 that are chronically infected with HIV, which con-
sistently produces a low level of virus particles. ACH2 
and A3.01 cells were maintained in RPMI 1640 supple-
mented with 10  mM HEPES, penicillin–streptomycin 
(100  µg/ml), 2  mM  l-glutamine and 10% FBS. HUT-
78HIV is a T lymphocyte cell line chronically infected 
with HIV-1SF2. HUT-78HIV and uninfected HUT-78 
cells were grown in RPMI 1640 with penicillin–strep-
tomycin (100 µg/ml) and 10% of FBS. U1HIV is a U937 
monocytic cell line infected with HIV, which maintains 
low constitutive expression of virus. U1HIV and U937 
cells were maintained in RPMI 1640 supplemented with 
penicillin–streptomycin (100 µg/ml), 2 mM l-glutamine 
and 10% FBS. Co-culture of HAECs with HIV-1-infected 
cells was performed by adding ACH2, U1HIV, or HUT-
78HIV to a monolayer of HAEC in 12 well plates and sub-
sequently incubating for 5 days. ACH2 and U1HIV cells 
were pre-treated with phorbol 12-myristate 13-acetate 
(PMA, 10−8 M) for 1–2 days to promote HIV replication. 
PMA stimulated and un-stimulated ACH2 or U1HIV 
were co-cultured with HAECs. Controls consisted of 
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HAECs cultured alone or co-cultured with HIV-free 
parental cells A3.01, U937 and HUT-78. For subcellular 
fractionation, HIV-infected cells were added to HAECs 
at 60–70% confluency in 100-mm culture dishes and 
incubated for 5  days. HUT-78HIV cells were cultured 
for 3–4  days allowing virus to reach peak production 
at which point they were co-cultured with HAECs. The 
culture medium ratio for HAECs and HIV-infected cells 
is 1:1. Non-adherent cells were removed and adherent 
HAECs were checked by microscopy to ensure removal 
of HIV-infected cells before harvesting. Afterwards, 
HAECs were cultured in regular ECM (basal medium), or 
in serum free medium containing 0.1% BSA and choles-
terol (40 μg/ml) for 36 h, followed by serum free medium 
without or with HDL (50 μg/ml) for 1–2 h. Nef treatment 
was carried out by growing HAECs to 70–80% conflu-
ency in 100-mm culture dishes with further incubation of 
the cells in the presence of recombinant Nef (100 ng/ml) 
for 72 h.
Cholesterol efflux
To determine cholesterol efflux by HDL, HAECs were 
co-cultured with HIV-infected cells (ACH2, HUT-
78HIV, U1HIV) or HIV-free parental cell lines (A3.01, 
HUT-78, U937) at a ratio of 1:3 for 5 days, respectively. 
ACH2 and U1HIV were pretreated with PMA (10−8 M) 
for 48 h before co-culture. HAECs and HUT-78HIV cells 
were co-cultured at ratio 1:1 or 1:5 for 7 days and at ratio 
1:3 for 3 and 7 days. HAECs were also co-cultured with 
PMA (10−8 M) pre-treated (for 48 h) U1HIV or U937 at 
ratio of 1:3 and incubated for 7 days. HIV-infected cells 
were then removed and HAECs were rinsed with serum 
free medium and labeled with 1 μCi/ml [3H] cholesterol 
and incubated for 36–48 h. Cells were washed gently and 
cultured for an additional 18 h in serum free medium in 
the presence or absence of 50  μg/ml HDL (Biomedical 
Technologies Inc., Stoughton, MA, USA). HDL or medi-
ated cholesterol efflux was determined as described pre-
viously [28]. Cholesterol efflux by HDL was measured as 
the total percentage of radiolabeled cholesterol appearing 
in the medium in the presence of HDL after subtraction 
of values of HDL-free medium as described previously 
[28]. To determine cholesterol efflux from HAECs by 
apoA-I, cells were labeled with 1 μCi/ml [3H] cholesterol 
for 24 h. Cells were treated or not with 3 µM LXR agonist 
TO-901317 (Sigma) for 18 h. After additional culture for 
3, 6 or 24  h in presence or absence of 50 μg/ml apoA-
l (Biomedical Technologies Inc., Stoughton, MA, USA), 
counts per minute (CPM) radioactivity levels in culture 
medium and cell lysates were measured using liquid scin-
tillation counting. Results are cpm in medium as a per-
centage of cpm in medium plus cpm in cell lysates.
To determine the effect of Nef on cholesterol efflux 
in HAECs NL4-3 based Nef-positive (pBR43IeG-nef+) 
and Nef-negative (pBR43IeG-nef−) constructs were 
obtained from the NIH AIDS Research Program. Infec-
tious virus were generated by calcium phosphate trans-
fection of 293T cells [27]. SupT1 cells were infected with 
pBR43IeG-nef+ (HIV WT) or pBR43IeG-nef− (HIV 
Nef−) at a multiplicity of infection (MOI) of 0.005. 
Twenty-four hours post infection cells were co-cultured 
with HAECs at ratio 5:1 and medium ratio 1:1 and incu-
bated further for 5  days. SupT1 cells were removed 
carefully and cholesterol efflux to HDL in HAECs was 
measured as described above. In a separate experiment, 
SupT1 cells were infected with HIV WT or HIV Nef- at 
an MOI 0.005 for 12 days. The supernatants were then 
harvested and clarified by 3,000 rpm centrifugation and 
added to HAECs culture at a medium ratio 1:1. HAEC 
cultures treated with supernatants from infected cells 
were further incubated for 5 days and cholesterol efflux 
to HDL was analyzed. To further explore the effect of 
Nef on HDL mediated cholesterol efflux in HAECs 
exogenous Nef was added at concentrations of 20, 50, 
and 100  ng/ml. Cells were incubated for 3  days and 
cholesterol efflux by HDL was measured as described 
above.
Sodium carbonate based isolation of Cav‑1 enriched 
membrane fractions
Human aortic endothelial cells from co-culture with 
HIV infected cells or Nef treated HAECs were harvested 
using 2  ml of ice-cold 500  mM sodium bicarbonate 
(Na2CO3) buffer containing 1 mM sodium orthovanadate 
(Na3VO4), 1 mM sodium fluoride (NaF), 44 μg/ml phe-
nylmethylsulfonyl fluoride (PMSF), and a protease inhibi-
tor mixture [61, 62]. After a 30-min incubation at 4°C, 
the cells were homogenized with 20 strokes on ice using 
a pre-chilled Dounce homogenizer and then sonicated 
with three 20-s bursts. Equal amounts of protein for each 
sonicated sample was adjusted to 45% sucrose by add-
ing an equal volume of 90% sucrose in 2-(N-morpholino)
ethanesulfonic acid (MES)-buffered saline (MBS) to give 
a final volume of 4 ml. The sample was placed in a Beck-
mann ultracentrifuge tube and overlaid with 4 ml of 35% 
sucrose, followed by an overlay of 4  ml of 5% sucrose, 
both in MBS containing 250  mM Na2CO3. The sucrose 
gradient was centrifuged at 39,000  rpm for 19  h at 4°C 
in a swing out Beckmann SW41 rotor. A total of 12 frac-
tions, 1 ml each, from each gradient were collected from 
top down. Three hundred microliters of each fraction was 
precipitated with 10% trichloroacetic acid and washed 
with acetone. Each fraction was analyzed by SDS-PAGE 
and the protein of interest was detected.
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Determination of cell cholesterol content
Human aortic endothelial cells were incubated in regu-
lar ECM culture basal medium or in serum free medium 
containing cholesterol and 1% fatty acid free BSA for 
36 h, and cellular cholesterol content was assayed using 
the Amplex Red cholesterol Assay Kit (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer’s protocol.
Western blotting
Human aortic endothelial cells were extracted using lysis 
buffer [50 mM Tris pH 7.5,100 mM NaCl, 1 mM EDTA, 
0.1% (v/v) Triton X-100, 10  mM NaF, 1  mM PMSF, 
and 1  mM Na3VO4] with a complete protease Inhibi-
tor mixture (Roche Diagnostics, Indianapolis, IN, USA) 
and subjected to SDS-PAGE followed by Western blot 
with the appropriate primary antibody overnight at 4°C 
and horseradish peroxidase-conjugated secondary anti-
body for 1  h at room temperature. For determination 
of Nef expression, culture medium from HIV-infected 
cells was harvested and clarified at 3,000  rpm centrifu-
gation. Cell culture supernatants were precipitated with 
trichloroacetic acid TCA (10%) and pellets were collected 
at 14,000  rpm centrifugation. Pellets were washed four 
times with ice-cold acetone and resuspended in 2× SDS 
loading buffer. Protein bands were detected by an ECL 
kit [chemiluminescent immunodetection system (Amer-
sham, Piscataway, NJ, USA)]. Antibodies used for immu-
noblots were mouse anti-Phospho-Caveolin-1(pY14) (BD 
Biosciences, San Jose, CA, USA), rabbit anti-Caveolin-1 
(Cell Signaling Technology Inc. Danvers, MA, USA), 
anti-Flotillin-1 (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), anti-ß-actin protein, anti-ß Tubulin (Sigma, 
St. Louis, MO, USA), anti-Nef (the NIH AIDS Research 
Program), mouse monoclonal anti-ABCA1, rabbit SR-B1 
antibody, and ABCG1 antibody (Novus Biologicals).
Cav‑1 phosphorylation assays
Human aortic endothelial cells were grown to 90% con-
fluency, subsequently washed twice with 1× Hank’s 
Balanced Salt Solution (HBSS) and replaced with fresh 
complete growth medium. Cells were then treated with 
150  ng/ml Nef and collected at various time periods 
ranging from 5 to 60 min. Cells were lysed and subjected 
to Western blotting as described above.
Reactive oxygen species (ROS) measurement
OxiSelect™ In Vitro ROS Assay Kit (Cellbiolabs, San 
Diego, CA, USA) was used to measure ROS according 
to the manufacturer’s protocol. Briefly, HAECs were first 
pretreated with 1  mM 2′,7′-dichlorodihydrofluorescein 
diacetate (DCFH-DA) a cell permeable probe oxidized 
to elicit fluorescence by ROS for 60  min at 37°C. Cells 
were then treated with recombinant Nef at 100  ng/ml 
for various time points (0–60 min), or co-cultured with 
HUT78HIV at a 1:5 ratio for 3 h. After Nef treatment or 
co-culture, the HAECs were washed and lysed and fur-
ther subjected to fluorescent detection by Synergy™ HT 
Multi-Detection Microplate Reader (Bio-Tek Instru-
ments, Inc.) at 480 nm/530 nm.
Statistical analysis
Student’s t-test was applied to analyze the differences 
between sets of data. All analyses were performed with 
SPSS 12.0.1 for Windows, and were considered signifi-
cant at P < 0.05.
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